

Title (en)
LASSA VACCINE

Title (de)
LASSA-IMPfstoff

Title (fr)
VACCIN CONTRE LASSA

Publication
EP 3727411 A2 20201028 (EN)

Application
EP 18857393 A 20181220

Priority
• US 201762609155 P 20171221
• IB 2018001620 W 20181220

Abstract (en)
[origin: WO2019123018A2] The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.

IPC 8 full level
A61K 35/76 (2015.01); **A61K 39/12** (2006.01); **C12N 15/87** (2006.01)

CPC (source: EP KR US)
A61K 35/76 (2013.01 - EP KR); **A61K 39/12** (2013.01 - EP); **A61K 39/165** (2013.01 - KR US); **A61P 31/14** (2018.01 - KR US); **C07K 14/005** (2013.01 - EP KR US); **C12N 7/00** (2013.01 - US); **C12N 15/86** (2013.01 - EP KR US); **A61K 2039/5256** (2013.01 - EP KR); **A61K 2039/54** (2013.01 - US); **A61K 2039/572** (2013.01 - US); **C12N 2760/10022** (2013.01 - EP KR US); **C12N 2760/10023** (2013.01 - US); **C12N 2760/10034** (2013.01 - EP KR US); **C12N 2760/10043** (2013.01 - US); **C12N 2760/10052** (2013.01 - US); **C12N 2760/10071** (2013.01 - EP KR US); **C12N 2760/18423** (2013.01 - EP KR US); **C12N 2760/18434** (2013.01 - EP KR US); **C12N 2760/18443** (2013.01 - EP KR US); **C12N 2760/18452** (2013.01 - US); **C12N 2760/18471** (2013.01 - EP KR US)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2019123018 A2 20190627; **WO 2019123018 A3 20190801**; AU 2018392826 A1 20200618; CA 3085224 A1 20190627; CN 111886342 A 20201103; EP 3727411 A2 20201028; JP 2021507707 A 20210225; JP 2024009058 A 20240119; KR 20200104343 A 20200903; MX 2020006476 A 20201210; SG 11202004899S A 20200629; US 11976305 B2 20240507; US 2020308555 A1 20201001

DOCDB simple family (application)
IB 2018001620 W 20181220; AU 2018392826 A 20181220; CA 3085224 A 20181220; CN 201880082649 A 20181220; EP 18857393 A 20181220; JP 2020534373 A 20181220; JP 2023192505 A 20231110; KR 20207021052 A 20181220; MX 2020006476 A 20181220; SG 11202004899S A 20181220; US 201816954592 A 20181220